ASLAN Pharmaceuticals

You are now leaving our web site.

The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.

ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.

I understand

News & Publications

Read about our latest product developments and partnerships, industry advances and events.

News

New data presented on ASLAN’s varlitinib at ESMO 2019

Today, ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497) announced  the presentation of new data from a phase 1b open-label, dose escalation study of varlitinib in combination with modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) chemotherapy to determine the safety, tolerability and maximum tolerated dose (MTD) in advanced solid tumours. The study findings were presented in a poster session at the 2019 European Society for Medical Oncology (ESMO) Congress.

For more information, please refer to the English or Chinese press release.